About gri bio inc - GRI
GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
GRI At a Glance
GRI Bio, Inc.
2223 Avenida De La Playa
La Jolla, California 92037
| Phone | 1-619-400-1170 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -11,956,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GRI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.572 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.625 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.009 |
GRI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,989,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GRI Liquidity
| Current Ratio | 3.251 |
| Quick Ratio | 3.251 |
| Cash Ratio | 3.114 |
GRI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -165.998 |
| Return on Equity | -238.167 |
| Return on Total Capital | -196.677 |
| Return on Invested Capital | -236.145 |
GRI Capital Structure
| Total Debt to Total Equity | 1.182 |
| Total Debt to Total Capital | 1.168 |
| Total Debt to Total Assets | 0.819 |
| Long-Term Debt to Equity | 0.25 |
| Long-Term Debt to Total Capital | 0.247 |